Sunshine Biopharma (NASDAQ:SBFM – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Sunshine Biopharma to similar companies based on the strength of its dividends, analyst recommendations, institutional ownership, earnings, valuation, profitability and risk.
Volatility & Risk
Sunshine Biopharma has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, Sunshine Biopharma’s peers have a beta of -0.04, indicating that their average stock price is 104% less volatile than the S&P 500.
Profitability
This table compares Sunshine Biopharma and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sunshine Biopharma | -18.89% | -26.55% | -21.30% |
| Sunshine Biopharma Competitors | -2,398.26% | -203.62% | -15.08% |
Valuation & Earnings
This table compares Sunshine Biopharma and its peers revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Sunshine Biopharma | $36.31 million | -$5.97 million | -0.01 |
| Sunshine Biopharma Competitors | $16.51 billion | $3.17 billion | 562.76 |
Sunshine Biopharma’s peers have higher revenue and earnings than Sunshine Biopharma. Sunshine Biopharma is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Analyst Ratings
This is a summary of current recommendations and price targets for Sunshine Biopharma and its peers, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sunshine Biopharma | 1 | 1 | 0 | 0 | 1.50 |
| Sunshine Biopharma Competitors | 7844 | 13796 | 25806 | 1039 | 2.41 |
As a group, “Pharmaceuticals” companies have a potential upside of 24.69%. Given Sunshine Biopharma’s peers stronger consensus rating and higher possible upside, analysts clearly believe Sunshine Biopharma has less favorable growth aspects than its peers.
Institutional & Insider Ownership
42.0% of Sunshine Biopharma shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 0.4% of Sunshine Biopharma shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Sunshine Biopharma peers beat Sunshine Biopharma on 9 of the 13 factors compared.
Sunshine Biopharma Company Profile
Sunshine Biopharma, Inc. is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for cancer and other medical conditions. Its lead oncology candidate, Adva-27a, is an investigational small-molecule drug designed to inhibit topoisomerase II, an enzyme involved in cancer-cell replication. The company has studied the compound in preclinical models, including models of breast cancer and multidrug-resistant tumors. In addition to its drug-development activities, Sunshine Biopharma has expanded into the pharmaceutical products business through its Canadian operations.
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
